Compare Neurocrine Biosciences Inc (NBIX) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nu Holdings Ltd — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while Nu Holdings Ltd trades at $13.65 (market cap $66.85B). The key difference: Nu Holdings Ltd is far larger — about 4× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NBIX | NU | |
|---|---|---|
Market Cap | $16.76B | $66.85B |
Sector | Health | Financials |
52-Week High | $185.50 | $18.76 |
52-Week Low | $123.10 | $11.60 |
Enterprise Value | $16.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Nu Holdings (NU) trades at $13.84, down 1.98% with a bearish technical outlook. The company shows strong fundamental growth with revenue increasing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Recent earnings show mixed results with two misses but a beat in Q3 2025. Analyst consensus remains bullish with a $14.98 price target despite recent price weakness.
Nu presents a compelling growth story with expanding profitability and market position in Latin American banking. Key risks include unsecured credit exposure and regional economic volatility. The current valuation at 21.35 P/E offers potential upside if the company maintains its growth trajectory and executes on expansion plans in Brazil and Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
